Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 2,659.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,868 shares of the company’s stock after purchasing an additional 15,293 shares during the period. Daiwa Securities Group Inc.’s holdings in Autolus Therapeutics were worth $55,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of AUTL. Perceptive Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 4th quarter worth approximately $11,793,000. Price T Rowe Associates Inc. MD boosted its position in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. BNP Paribas Financial Markets boosted its holdings in Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock valued at $736,000 after acquiring an additional 111,131 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Autolus Therapeutics by 74.5% in the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock valued at $8,810,000 after purchasing an additional 1,080,897 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new position in shares of Autolus Therapeutics in the fourth quarter worth $768,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AUTL has been the subject of several analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, June 17th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.70.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $3.84 on Wednesday. Autolus Therapeutics plc has a 1 year low of $2.01 and a 1 year high of $7.45. The company’s 50 day simple moving average is $4.10 and its 200 day simple moving average is $4.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -3.20 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, sell-side analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.